The Debrief revisits each presentation from our 2026 Summit, one speaker at a time. In Part I, Neal Millar makes the case that the field has underperformed on tendinopathy because it has paid too little attention to the biology—and lays out the inflammatory pathways, and emerging therapies, that point to where treatment is headed. Read this edition with full references at traversecitytendonsummit.com.